Bone health evaluation one year after aromatase inhibitors completion

Breast cancer patients treated with aromatase inhibitors (AIs) experience increased bone loss during their treatment. However, there is little information about bone mineral density (BMD) after completing AI-treatment. The present study aimed to assess BMD changes one year after AI-therapy completio...

Descripción completa

Detalles Bibliográficos
Autores: Pineda-Moncusí, Marta, Servitja Tormo, Sonia, Casamayor, Guillem, Cos, Maria Lourdes, Rial, Abora, Rodriguez-Morera, Jaime, Tusquets Trias de Bes, Ignacio, Díez Pérez, Adolfo, Garcia Giralt, Natàlia, Nogués Solán, Xavier
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2018
País:España
Institución:Universitat Pompeu Fabra
Repositorio:Repositorio Digital de la UPF
OAI Identifier:oai:repositori.upf.edu:10230/36862
Acceso en línea:http://hdl.handle.net/10230/36862
http://dx.doi.org/10.1016/j.bone.2018.09.010
Access Level:acceso abierto
Palabra clave:Ossos -- Malalties
Mama -- Càncer
Bone mineral density
Aromatase inhibitors
B-ABLE cohort
Bisphosphonates
Breast cancer
id ES_ffdefd1c6a42a7f940dcfa3f3c088ce6
oai_identifier_str oai:repositori.upf.edu:10230/36862
network_acronym_str ES
network_name_str España
repository_id_str
spelling Bone health evaluation one year after aromatase inhibitors completionPineda-Moncusí, MartaServitja Tormo, SoniaCasamayor, GuillemCos, Maria LourdesRial, AboraRodriguez-Morera, JaimeTusquets Trias de Bes, IgnacioDíez Pérez, AdolfoGarcia Giralt, NatàliaNogués Solán, XavierOssos -- MalaltiesMama -- CàncerBone mineral densityAromatase inhibitorsB-ABLE cohortBisphosphonatesBreast cancerBreast cancer patients treated with aromatase inhibitors (AIs) experience increased bone loss during their treatment. However, there is little information about bone mineral density (BMD) after completing AI-treatment. The present study aimed to assess BMD changes one year after AI-therapy completion. METHODS: Data were collected from 864 postmenopausal women treated with AI during 5 years (5y-AI group), or during 2-3 years after taking tamoxifen therapy (pTAM-AI group). Participants with osteoporosis were treated with oral bisphosphonates (BP). BMD changes in lumbar spine (LS), femoral neck (FN) and total hip (TH) between baseline, end of treatment, and at one year post-treatment were assessed using repeated-measures ANOVA. RESULTS: At the end of AI-treatment, 382 patients had available BMD values and 316 also had post-treatment BMD values. As expected, BMD levels were decreased at AI-completion in non-BP treated patients. After one year, LS BMD increased in both groups (5y-AI: +2.11% [95%CI: 1.55 to 2.68], p < 0.001; pTAM-AI: +1.00% [95%CI: 0.49 to 1.51], p < 0.001) compared with the end of AI-therapy, while values at FN and TH remained stable. On the other hand, BMD values of BP-treated patients were increased or maintained at the end of AI-treatment and also at post-treatment. CONCLUSIONS: At one year after AI-completion, FN and TH BMD remained reduced in non-BP treated women, while LS BMD was recovered in the 5y-AI group and partially recovered in the pTAM-AI group. BP treatment increased or maintained BMD values at the end of therapy and at one year post-treatment.Elsevier20192018info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/36862http://dx.doi.org/10.1016/j.bone.2018.09.010reponame:Repositorio Digital de la UPFinstname:Universitat Pompeu FabraInglésBone. 2018 Dec;117:54-9© Elsevier http://dx.doi.org/10.1016/j.bone.2018.09.010info:eu-repo/semantics/openAccessoai:repositori.upf.edu:10230/368622026-06-12T07:21:37Z
dc.title.none.fl_str_mv Bone health evaluation one year after aromatase inhibitors completion
title Bone health evaluation one year after aromatase inhibitors completion
spellingShingle Bone health evaluation one year after aromatase inhibitors completion
Pineda-Moncusí, Marta
Ossos -- Malalties
Mama -- Càncer
Bone mineral density
Aromatase inhibitors
B-ABLE cohort
Bisphosphonates
Breast cancer
title_short Bone health evaluation one year after aromatase inhibitors completion
title_full Bone health evaluation one year after aromatase inhibitors completion
title_fullStr Bone health evaluation one year after aromatase inhibitors completion
title_full_unstemmed Bone health evaluation one year after aromatase inhibitors completion
title_sort Bone health evaluation one year after aromatase inhibitors completion
dc.creator.none.fl_str_mv Pineda-Moncusí, Marta
Servitja Tormo, Sonia
Casamayor, Guillem
Cos, Maria Lourdes
Rial, Abora
Rodriguez-Morera, Jaime
Tusquets Trias de Bes, Ignacio
Díez Pérez, Adolfo
Garcia Giralt, Natàlia
Nogués Solán, Xavier
author Pineda-Moncusí, Marta
author_facet Pineda-Moncusí, Marta
Servitja Tormo, Sonia
Casamayor, Guillem
Cos, Maria Lourdes
Rial, Abora
Rodriguez-Morera, Jaime
Tusquets Trias de Bes, Ignacio
Díez Pérez, Adolfo
Garcia Giralt, Natàlia
Nogués Solán, Xavier
author_role author
author2 Servitja Tormo, Sonia
Casamayor, Guillem
Cos, Maria Lourdes
Rial, Abora
Rodriguez-Morera, Jaime
Tusquets Trias de Bes, Ignacio
Díez Pérez, Adolfo
Garcia Giralt, Natàlia
Nogués Solán, Xavier
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Ossos -- Malalties
Mama -- Càncer
Bone mineral density
Aromatase inhibitors
B-ABLE cohort
Bisphosphonates
Breast cancer
topic Ossos -- Malalties
Mama -- Càncer
Bone mineral density
Aromatase inhibitors
B-ABLE cohort
Bisphosphonates
Breast cancer
description Breast cancer patients treated with aromatase inhibitors (AIs) experience increased bone loss during their treatment. However, there is little information about bone mineral density (BMD) after completing AI-treatment. The present study aimed to assess BMD changes one year after AI-therapy completion. METHODS: Data were collected from 864 postmenopausal women treated with AI during 5 years (5y-AI group), or during 2-3 years after taking tamoxifen therapy (pTAM-AI group). Participants with osteoporosis were treated with oral bisphosphonates (BP). BMD changes in lumbar spine (LS), femoral neck (FN) and total hip (TH) between baseline, end of treatment, and at one year post-treatment were assessed using repeated-measures ANOVA. RESULTS: At the end of AI-treatment, 382 patients had available BMD values and 316 also had post-treatment BMD values. As expected, BMD levels were decreased at AI-completion in non-BP treated patients. After one year, LS BMD increased in both groups (5y-AI: +2.11% [95%CI: 1.55 to 2.68], p < 0.001; pTAM-AI: +1.00% [95%CI: 0.49 to 1.51], p < 0.001) compared with the end of AI-therapy, while values at FN and TH remained stable. On the other hand, BMD values of BP-treated patients were increased or maintained at the end of AI-treatment and also at post-treatment. CONCLUSIONS: At one year after AI-completion, FN and TH BMD remained reduced in non-BP treated women, while LS BMD was recovered in the 5y-AI group and partially recovered in the pTAM-AI group. BP treatment increased or maintained BMD values at the end of therapy and at one year post-treatment.
publishDate 2018
dc.date.none.fl_str_mv 2018
2019
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/36862
http://dx.doi.org/10.1016/j.bone.2018.09.010
url http://hdl.handle.net/10230/36862
http://dx.doi.org/10.1016/j.bone.2018.09.010
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Bone. 2018 Dec;117:54-9
dc.rights.none.fl_str_mv © Elsevier http://dx.doi.org/10.1016/j.bone.2018.09.010
info:eu-repo/semantics/openAccess
rights_invalid_str_mv © Elsevier http://dx.doi.org/10.1016/j.bone.2018.09.010
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositorio Digital de la UPF
instname:Universitat Pompeu Fabra
instname_str Universitat Pompeu Fabra
reponame_str Repositorio Digital de la UPF
collection Repositorio Digital de la UPF
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869425813142634496
score 15,811543

Similares en LA Referencia